Zsófia Pénzváltó
Zsófia Pénzváltó
Verified email at ucdavis.edu
Title
Cited by
Cited by
Year
Parallel evolution under chemotherapy pressure in 29 breast cancer cell lines results in dissimilar mechanisms of resistance
B Tegze, Z Szállási, I Haltrich, Z Pénzváltó, Z Tóth, I Likó, B Győrffy
PloS one 7 (2), e30804, 2012
532012
MEK1 is associated with carboplatin resistance and is a prognostic biomarker in epithelial ovarian cancer
Z Pénzváltó, A Lánczky, J Lénárt, N Meggyesházi, T Krenács, ...
BMC cancer 14 (1), 837, 2014
482014
Identifying resistance mechanisms against five tyrosine kinase inhibitors targeting the ERBB/RAS pathway in 45 cancer cell lines
Z Pénzváltó, B Tegze, AM Szász, Z Sztupinszki, I Likó, A Szendrői, ...
PloS one 8 (3), e59503, 2013
232013
Biomarkers for systemic therapy in ovarian cancer
Z Pénzváltó, P Surowiak, B Gyorffy
Current cancer drug targets 14 (3), 259-273, 2014
122014
A network-based target overlap score for characterizing drug combinations: high correlation with cancer clinical trial results
B Ligeti, Z Pénzváltó, R Vera, B Győrffy, S Pongor
PloS one 10 (6), e0129267, 2015
102015
Validation of rnai silencing efficiency using gene array data shows 18.5% failure rate across 429 independent experiments
G Munkácsy, Z Sztupinszki, P Herman, B Bán, Z Pénzváltó, N Szarvas, ...
Molecular Therapy-Nucleic Acids 5, e366, 2016
92016
Glucose uptake and intracellular pH in a mouse model of ductal carcinoma in situ (DCIS) suggests metabolic heterogeneity
RC Lobo, NE Hubbard, P Damonte, H Mori, Z Pénzváltó, C Pham, ...
Frontiers in cell and developmental biology 4, 93, 2016
72016
Gene expression based multigene prognostic and predictive tests in breast cancer
Z Penzvalto, Z Mihaly, B Gyorffy
Magyar Onkologia 53 (4), 351-359, 2009
32009
Pathobiology of the 129:Stat1−/− mouse model of human age-related ER-positive breast cancer with an immune infiltrate-excluded phenotype
H Mori, JQ Chen, RD Cardiff, Z Pénzváltó, NE Hubbard, L Schuetter, ...
Breast Cancer Research 19 (1), 102, 2017
22017
Génexpresszió mérésén alapuló multigénes prognosztikai és prediktív előrejelzés emlőtumorokban
Z Pénzváltó, Z Mihály, B Győrffy
Magyar onkologia 53 (4), 351-359, 2009
22009
A Syngeneic ErbB2 Mammary Cancer Model for Preclinical Immunotherapy Trials
Z Pénzváltó, JQ Chen, CG Tepper, RR Davis, MT Silvestrini, ...
Journal of mammary gland biology and neoplasia 24 (2), 149-162, 2019
12019
Validation of RNAi Silencing Efficiency Using Gene Array Data shows 18.5% Failure Rate across 429 Independent Experiments
M Gyöngyi, S Zsófia, H Péter, B Bence, P Zsófia, S Nóra, G Balázs
2016
A network-based target overlap score for characterizing drug combinations: High correlation with cancer clinical trial results
L Balázs, P Zsófia, R Vera, G Balázs, P Sándor
2015
Génexpresszió alapú prediktív biomarkerek a szolid tumorok szisztémás terápiájában
Z Pénzváltó
2015
Inhibition of MEK1 increases carboplatin sensitivity in ovarian cancer.
B Gyorffy, A Lanczky, I Pete, C Denkert, T Krenacs, N Meggyeshazi, ...
Journal of Clinical Oncology 32 (15_suppl), 5557-5557, 2014
2014
Identifying predictive biomarkers of carboplatin resistance in ovarian cancer
Z Penzvalto, A Lanczky, B Gyorffy
EUROPEAN JOURNAL OF CANCER 49, S737-S738, 2013
2013
Identifying Resistance Mechanisms against Five Tyrosine Kinase Inhibitors Targeting the ERBB/RAS Pathway in 45 Cancer Cell Lines
P Zsófia, T Bálint, SA Marcell, S Zsófia, L István, S Attila, R Schäfer, ...
2013
Identifying Resistance Mechanisms against Five Tyrosine Kinase Inhibitors Targeting
Z Pénzváltó, B Tegze, AM Szász, Z Sztupinszki, I Likó
2013
Identifying resistance biomarkers against five clinically approved tyrosine kinase inhibitors in 45 cell lines.
Z Pénzváltó, B Tegze, AM Szasz, R Schäfer, B Gyorffy
Journal of Clinical Oncology 30 (15_suppl), e21005-e21005, 2012
2012
The system can't perform the operation now. Try again later.
Articles 1–19